Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30128999 | 1.00 | IDO1 (0.48) | IDO1ALOX15KMT2AMEN1MAPT | |
| SCHEMBL24877880 | 0.93 | IDO1 (0.53) | IDO1ALOX15KMT2AMEN1MAPT | |
| SCHEMBL30129204 | 0.93 | IDO1 (0.53) | IDO1ALOX15KMT2AMEN1MAPT | |
| SCHEMBL30128924 | 0.93 | ALOX15 (0.48) | IDO1ALOX15KMT2AMEN1MAPT | |
| SCHEMBL24877794 | 0.93 | ALOX15 (0.44) | IDO1ALOX15KMT2AMEN1MAPT | |
| SCHEMBL30129529 | 0.93 | ALOX15 (0.44) | IDO1ALOX15KMT2AMEN1MAPT | |
| SCHEMBL24877805 | 0.93 | ALOX15 (0.48) | IDO1ALOX15KMT2AMEN1MAPT | |
| SCHEMBL24878014 | 0.91 | ALOX15 (0.47) | IDO1ALOX15KMT2AMEN1MAPT | |
| SCHEMBL30128928 | 0.91 | ALOX15 (0.47) | IDO1ALOX15KMT2AMEN1MAPT | |
| SCHEMBL24877807 | 0.91 | IDO1 (0.47) | IDO1ALOX15KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | IDO1 1/4885ALOX15 633/4885KMT2A 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.